Shots:
- The ongoing P-II/III CAPELLA trial evaluating the antiviral activity of lenacapavir (SC, every 6mos.) + other antiretroviral agents vs PBO in 36 patients in a ratio (2:1) with multi-drug resistant HIV-1 infection. The trial is being conducted at research centers in North America, the EU & Asia
- The study demonstrated high rates of virologic suppression @26wks., viral load reduction from baseline of at least 0.5 log10 copies/mL for 14 days functional monothx. period (88% vs 17%), 81% of patients achieved an undetectable viral load, was generally well tolerated with no AEs
- If approved, the therapy will be the 1st capsid inhibitor & the only HIV-1 treatment option administered every 6mos.
Click here to read the full press release/ article | Ref: Gilead | Image: Reuters
The post Gilead Reports New Data of Lenacapavir in P-II/III CAPELLA Trial for the Treatment of HIV first appeared on PharmaShots.
